Zobrazeno 1 - 8
of 8
pro vyhledávání: '"R. Lagor, William"'
The low-density lipoprotein receptor (Ldlr) and apolipoprotein E (Apoe) germline knockout (KO) models have provided fundamental insights in lipid and atherosclerosis research for decades. However, testing new candidate genes in these models requires
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::274604b65c8c577bbae3dd32b171ec74
Autor:
De Giorgi, Marco, Jarrett, Kelsey, Burton, Jason, Doerfler, Alexandria, Hurley, Ayrea, Li, Ang, Hsu, Rachel, Furgurson, Mia N., Han, Jun, Borchers, Christoph H., R. Lagor, William
Hmg-CoA Reductase (Hmgcr) catalyzes the conversion of Hmg-CoA to mevalonate, which is the rate-limiting step in the cholesterol biosynthetic pathway. Hmgcr is the target of statins, which are the front line therapy for hypercholesterolemia. In additi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e173545ea1e62d96a73d7ea519b8405
Autor:
De Giorgi, Marco, Doerfler, Alexandria, Hurley, Ayrea, J. Walkey, Christopher, R. Lagor, William
Dolichol is a nonsterol isoprenoid derived from the mevalonate pathway. Dehydrodolichyl diphosphate synthase subunit (DHDDS) is a branch point enzyme that - in complex with Nogo-B receptor (NgBR) - catalyzes the first committed step of dolichol biosy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d070245c7234dd40ce0cebb94d518227
Autor:
De Giorgi, Marco, Jarrett, Kelsey, Burton, Jason, Doerfler, Alexandria, Hurley, Ayrea, Li, Ang, Hsu, Rachel, Furgurson, Mia N., Han, Jun, Borchers, Christoph, R. Lagor, William
Hmg-CoA Reductase (Hmgcr) catalyzes the conversion of Hmg-CoA to mevalonate, which is the rate-limiting step in the cholesterol biosynthetic pathway. Hmgcr is the target of statins, which are the front line therapy for hypercholesterolemia. In additi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7ea01b863de73aa29ea92903f1f7003
Autor:
De Giorgi, Marco, Li, Ang, Hurley, Ayrea, Barzi, Mercedes, Doerfler, Alexandria, Smith, Harrison, Lin, Charles, Brown, Jonathan, Bissig, Karl-Dimiter, R. Lagor, William
The liver is an organ of particular interest for gene therapy, both for correcting inherited metabolic disorders, as well as a biofactory for secretion of therapeutic proteins. The CRISPR/Cas9 genome editing system has greatly improved specificity an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0eb4faa1c4a8946c825ef510b6fad9d7
Autor:
Doerfler, Alexandria, Han, Jun, Jarrett, Kelsey, Tang, Li, Jain, Antrix, Saltzman, Alexander, De Giorgi, Marco, Chuecos, Marcel, Hurley, Ayrea, Li, Ang, Morand, Pauline, Ayala, Claudia, Goodlett, David, Malovannaya, Anna, Martin, James, Vallim, Thomas, Shroyer, Noah, R. Lagor, William
BACKGROUND: The intestine occupies the critical interface between cholesterol absorption and excretion. Surprisingly little is known about the role of de novo cholesterol synthesis in this organ, and its relationship to whole body cholesterol homeost
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50ad8fccf360f4425746326011ab2de2
Autor:
De Giorgi, Marco, Hurley, Ayrea, Doerfler, Alexandria, Furgurson, Mia N., Chuecos, Marcel, Hyde, Sarah, Chickering, Tyler, Lefebvre, Stephanie, Qin, June, Bissig, Karl-Dimiter, Castoreno, Adam B., Jadhav, Vasant, R. Lagor, William
Targeted integration of therapeutic transgenes into a common genomic site could be used to treat a broad range of liver diseases. Recently, we showed that the Apolipoprotein A1 (Apoa1) locus could be targeted with adeno-associated viral (AAV) deliver
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b3661111ce2095c6628c27b04d94885
Autor:
De Giorgi, Marco, Jarrett, Kelsey, Burton, Jason, Doerfler, Alexandria, Hurley, Ayrea, Li, Ang, Hsu, Rachel, Furgurson, Mia N., Han, Jun, Borchers, Christoph H., R. Lagor, William
Hmg-CoA Reductase (Hmgcr) catalyzes the conversion of Hmg-CoA to mevalonate, which is the rate-limiting step in the cholesterol biosynthetic pathway. Hmgcr is the target of statins, which are the front line therapy for hypercholesterolemia. In additi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40c5c3fc67e8273933c7797ee69cc973